Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.

J Clin Invest. 1996 Feb 1;97(3):865-9. Unique Identifier : AIDSLINE MED/96189969
Kaveri S; Vassilev T; Hurez V; Lengagne R; Lefranc C; Cot S; Pouletty P; Glotz D; Kazatchkine MD; Institut National de la Sante et de la Recherche Medicale U430,; Hopital Broussais, Paris, France.

Abstract: Intravenous immunoglobulin (IVIg) is increasingly used for the treatment of autoimmune diseases and the prevention of infections and of graft versus host reactions in recipients of allogeneic bone marrow transplants. The immunomodulatory effects of IVIg are largely dependent on their ability to interact with membrane molecules of lymphocytes. We report here that IVIg recognizes the B07.75-84 peptide, corresponding to a conserved region of the alpha I helix of the first domain of HLA-B7 01, which represents a nonpolymorphic determinant of HLA class I molecules. Intact IVIg and its F(ab')2 fragments bound to the peptide as well as to purified soluble HLA and to HLA on a human T cell line. Binding of IVIg to HLA was assessed by ELISA, immunofluorescence, and real-time analysis of the interaction using the BIAlite system. The binding of antipeptide antibodies to HLA was inhibited by free peptide. Antipeptide antibodies isolated from IVIg by affinity chromatography inhibited CD8 cell-mediated cytotoxicity of an influenza virus-specific human T cell line. The presence in IVIg of antibodies to critical regions of HLA class 1 molecules suggests a possible role for IVIg in modulation of class-I-restricted cellular interactions in the immune response.

Keywords: Amino Acid Sequence Antibody Specificity Autoimmune Diseases/THERAPY Conserved Sequence Cytotoxicity, Immunologic/*DRUG EFFECTS CD8-Positive T-Lymphocytes/*DRUG EFFECTS Graft vs Host Disease/PREVENTION & CONTROL Human HLA-B7 Antigen/GENETICS/*IMMUNOLOGY Immunoglobulins, Intravenous/IMMUNOLOGY/*PHARMACOLOGY/THERAPEUTIC USE Molecular Sequence Data Peptide Fragments/GENETICS/*IMMUNOLOGY Support, Non-U.S. Gov't JOURNAL ARTICLE
960830
M9681189

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .